Epigenetics of colorectal cancer: biomarker and therapeutic potential
G Jung, E Hernández-Illán, L Moreira… - Nature reviews …, 2020 - nature.com
Colorectal cancer (CRC), a leading cause of cancer-related death worldwide, evolves as a
result of the stepwise accumulation of a series of genetic and epigenetic alterations in the …
result of the stepwise accumulation of a series of genetic and epigenetic alterations in the …
The multi-factorial nature of clinical multidrug resistance in cancer
Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …
Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer
WM Grady - Advances in cancer research, 2021 - Elsevier
Colorectal cancer is a leading cause of cancer related deaths worldwide. One of the
hallmarks of cancer and a fundamental trait of virtually all gastrointestinal cancers is …
hallmarks of cancer and a fundamental trait of virtually all gastrointestinal cancers is …
How to stomach an epigenetic insult: the gastric cancer epigenome
Gastric cancer is a deadly malignancy afflicting close to a million people worldwide. Patient
survival is poor and largely due to late diagnosis and suboptimal therapies. Disease …
survival is poor and largely due to late diagnosis and suboptimal therapies. Disease …
Next-generation of selective histone deacetylase inhibitors
Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for cancer
treatment. HDACs inhibitors (HDACis) have been successfully applied against a series of …
treatment. HDACs inhibitors (HDACis) have been successfully applied against a series of …
An update on colorectal cancer microenvironment, epigenetic and immunotherapy
K Jin, C Ren, Y Liu, H Lan, Z Wang - International immunopharmacology, 2020 - Elsevier
Colorectal cancer (CRC) is considered as the second most common cancer worldwide. For
the past few years, the role of immunotherapy has been extensively studied and it has been …
the past few years, the role of immunotherapy has been extensively studied and it has been …
[HTML][HTML] Gastric cancer in the era of precision medicine
X Liu, SJ Meltzer - Cellular and molecular gastroenterology and …, 2017 - Elsevier
Gastric cancer (GC) remains the third most common cause of cancer death worldwide, with
limited therapeutic strategies available. With the advent of next-generation sequencing and …
limited therapeutic strategies available. With the advent of next-generation sequencing and …
Recent considerations in the application of RAPTA‐C for cancer treatment and perspectives for its combination with immunotherapies
M Rausch, PJ Dyson… - Advanced …, 2019 - Wiley Online Library
The organometallic ruthenium (II)[Ru (arene) Cl2PTA] PTA‐1, 3, 5‐triaza‐7‐
phosphaadamantane compound, RAPTA‐C, represents an innovative anti‐cancer …
phosphaadamantane compound, RAPTA‐C, represents an innovative anti‐cancer …
The genomic impact of DNA CpG methylation on gene expression; relationships in prostate cancer
The process of DNA CpG methylation has been extensively investigated for over 50 years
and revealed associations between changing methylation status of CpG islands and gene …
and revealed associations between changing methylation status of CpG islands and gene …
Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment
YC Duan, YC Ma, WP Qin, LN Ding, YC Zheng… - European journal of …, 2017 - Elsevier
Abstract Lysine specific demethylase 1 (LSD1) and Histone deacetylases (HDACs) are
promising drug targets for cancers. Recent studies reveal an important functional interplay …
promising drug targets for cancers. Recent studies reveal an important functional interplay …